Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
1 other identifier
observational
130
1 country
1
Brief Summary
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2009
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2009
CompletedFirst Submitted
Initial submission to the registry
May 24, 2010
CompletedFirst Posted
Study publicly available on registry
June 3, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2013
CompletedOctober 17, 2013
October 1, 2013
3.5 years
May 24, 2010
October 15, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Identification of Human GBM CD Antigen Signature.
Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified.
3 Years
Secondary Outcomes (3)
Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood.
3 Years
Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.
3 Years
Prospective Evaluation of the Routine Medical History of GBM Patients.
3 Years
Study Arms (2)
GBM Patients
GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
Normal Controls
Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
Interventions
Eligibility Criteria
Participants will be recruited during routine interactions with the investigators.
You may qualify if:
- to 89 years of age
- Weight of at least 110 pounds
- Able to provide informed consent for self
You may not qualify if:
- Patients with active malignant tumors other than GBM
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Florida
Gainesville, Florida, 32610, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brent Reynolds, PhD
University of Florida
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 24, 2010
First Posted
June 3, 2010
Study Start
October 1, 2009
Primary Completion
April 1, 2013
Study Completion
April 1, 2013
Last Updated
October 17, 2013
Record last verified: 2013-10